Research Article

Etoposide Incorporated into Camel Milk Phospholipids Liposomes Shows Increased Activity against Fibrosarcoma in a Mouse Model

Hamzah M. Maswadeh,1 Ahmad N. Aljarbou,1 Mohammed S. Alorainy,2 Mansour S. Alsharidah,3 and Masood A. Khan4

1Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah 51412, Saudi Arabia
2Department of Pharmacology & Therapeutics, College of Medicine, Qassim University, Buraydah, Saudi Arabia
3Department of Physiology, College of Medicine, Qassim University, Buraydah, Saudi Arabia
4Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia

Correspondence should be addressed to Hamzah M. Maswadeh; msodh@qu.edu.sa

Received 16 September 2014; Revised 6 November 2014; Accepted 13 November 2014

Academic Editor: Wan-Liang Lu

Copyright © 2015 Hamzah M. Maswadeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Phospholipids were isolated from camel milk and identified by using high performance liquid chromatography and gas chromatography-mass spectrometry (GC/MS). Anticancer drug etoposide (ETP) was entrapped in liposomes, prepared from camel milk phospholipids, to determine its activity against fibrosarcoma in a murine model. Fibrosarcoma was induced in mice by injecting benzopyrene (BAP) and tumor-bearing mice were treated with various formulations of etoposide, including etoposide entrapped camel milk phospholipids liposomes (ETP-Cam-liposomes) and etoposide-loaded DPPC-liposomes (ETP-DPPC-liposomes). The tumor-bearing mice treated with ETP-Cam-liposomes showed slow progression of tumors and increased survival compared to free ETP or ETP-DPPC-liposomes. These results suggest that ETP-Cam-liposomes may prove to be a better drug delivery system for anticancer drugs.

1. Introduction

Cancer is a growing health concern around the world due to changes in environmental conditions and lifestyle. The existing treatment approaches have not been able to effectively deal with cancer and, therefore, continuing efforts are ongoing to explore novel strategies for cancer treatment.

Most clinical regimens comprise multiple non-cross-resistant anticancer agents [1]. DNA-modifying agents such as anthracycline-based topoisomerase II inhibitors and platinum-based drugs have been explored alone or in combination against ovarian, advanced breast cancer, and endometrial carcinoma [2–10]. Etoposide, a topoisomerase II inhibitor, is used in the chemotherapy of various types of cancers, including lymphoma, lung cancer, leukemia, and Kaposi’s sarcoma. Cancerous cells rely on more topoisomerase II than healthy cells; thus targeting this enzyme is one of the important strategies to control the multiplication of cancerous cells. Etoposide makes a ternary complex with topoisomerase II and DNA, causing DNA breakage and thus apoptosis [11]. Etoposide shows dose-limiting hematologic and gastrointestinal toxicity. Liposomal formulations of anticancer drugs, including etoposide, have been explored to increase their activity and to reduce their toxicity [12, 13].

Liposomes make an excellent drug delivery system as they are both biocompatible and biodegradable. They incorporate both lipophilic and hydrophilic drugs. Drug delivery systems have been shown to reverse the chances of drug resistance in cancer cells [14]. Moreover, liposomized anticancer formulations can circumvent drug efflux and achieve adequate drug concentrations in the target cells to enable tumor killing, because liposome-mediated disposition interacts well with drug efflux mediated by p-glycoprotein transporters [14, 15].

Evidently, if the liposomes are to be used for targeting extra-RES tissues, a key issue is to reduce the rate of uptake
by the RES to enable them to remain in the circulation longer. The effect of particle size in favor of small vesicles was recognized early [16]. It has been noted previously that vesicles with a mean diameter of 100 nm exhibit longer circulation times than smaller or larger vesicles with the same composition [17].

Camel milk is an important source of proteins and is widely exploited for human health [18]. Phospholipids (PLs) are the main constituents of the milk fat globule membrane (MFGM). MFGM is trilaminar, mainly consisting of proteins, surrounding the intracellular neutral lipids. This inner part is covered by a bilayer membrane derived from the secretory cell apical plasma membrane [19]. PLs are mainly located in the outer leaflet and are organized as a liquid-disordered phase coexisting with a liquid-ordered phase (also called a lipid raft) and the latter is rich in sphingomyelin and cholesterol [20, 21].

The aim of the present work was to extract and analyze the major PLs present in camel milk by using HPLC and GC/MS. The isolated total camel milk phospholipids were used to prepare SUVs liposomes and the latter were incorporated with etoposide. The in vivo activity of various etoposide formulations prepared in this study was tested against experimental fibrosarcoma in a murine model.

2. Materials and Methods

2.1. Materials. 1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), synthetic soya phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and lysophosphatidylcholine (LPC) standards were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Silica gel-60 and precoated thin layer chromatography (TLC) plates, triethylamine, acetonitrile, methanol, chloroform, and phosphoric acid of HPLC grade were purchased from Merck (Germany). Etoposide was obtained from Tocris Bioscience (UK). Sephadex G-75 was obtained from Fisher Scientific (Loughborough, UK). Camel milk was collected from a six-year-old red camel two months postdelivery lactation period from Aljarbou farm in Qassim, Saudi Arabia.

2.2. Extraction of Phospholipids from Camel Milk. Extraction of the whole lipid fraction was carried out from 500 mL of camel milk. The freeze drying technique was applied to avoid milk and water interference, as well as the interaction of phospholipids with both lipids and proteins, due to their amphiphilic properties [22]. The freeze-dried milk sample was extracted three times with methylene chloride (chloroform was replaced with methylene chloride due to toxicity). The residue was then extracted with a mixture of 1:1 (v/v) methylene chloride/methanol mixture and finally with 100% methanol. After evaporating the solvent mixtures, the lipid content was evaluated by thin layer chromatography (TLC) using methylene chloride: methanol: acetic acid: water (65:30:6:2) as developing system. The combined methylene chloride fraction was evaporated under vacuum, and the finally dried residue was subjected to vacuum liquid chromatography (VLC) using methylene chloride for neutral lipids and methanol for phospholipids [23]. The purified phospholipids were primarily evaluated by TLC and compared with standard phospholipids. Identification of individual phospholipids was achieved by GC-MS and HPLC.

2.3. HPLC System and Conditions. The analytical HPLC system consisted of an Alliance 1525 separation module, automatic HPLC system equipped with UV/Vis detector 2489 (Waters, USA). The separation was achieved on Spherisorb C8 column (4.6 x 250 mm; particle size 5 μm) at 45°C. The mobile phase consisted of A: acetonitrile/methanol/n-hexane (90:3:7 v/v) with 0.08% triethylamine (TEA) and B: acetonitrile/water/phosphoric acid (75:25:1 v/v) with 0.08% TEA. The rate of flow was 1-2 mL/min with an injection volume of 20 μL. The monitoring wavelength was 210 nm.

2.4. GC/MS System and Conditions. The GC-MS analysis was performed in a Shimadzu GC 2014 series equipped with a flame ionization detector. A DB-35 capillary column (30 mm x 0.25 mm x 25 μm). The initial temperature was 80°C for 4 min after injection, increased to 280°C with a final hold at 280°C for 25 min. The injector and detector temperature were maintained at 270°C. Helium was used as a carrier gas at a flow rate of 0.7 mL/min.

2.5. Liposome Preparation and Drug Encapsulation. Liposomes from DPPC and camel milk phospholipids containing etoposide were prepared. The thin film hydration method was used. Briefly, liposomes from DPPC or camel milk phospholipids were prepared by dissolving the lipid and etoposide in a mixture of chloroform/methanol. The solvent was subsequently slowly evaporated in a rotary evaporator. Multilamellar large vesicles (MLVs) were formed by adding normal saline. The preparation was then treated by freeze-thaw for 10 cycles. The so-produced vesicles were subsequently extruded 10 times through 200 nm and 100 nm polycarbonate membranes using an extruder device Lipex Biomembranes Inc., heated at 50°C. The final lipid concentration of the formulations was 10 mg/mL. Subsequently, the extruded vesicles with encapsulated etoposide were separated from unentrapped etoposide by filtration through a Sephadex G-75 column. Vesicles were disrupted with ethanol and the entrapped etoposide was assayed by HPLC method as described above.

2.6. Characterization of Liposomes. An optical microscope (SZII, Olympus, Tokyo, Japan) equipped with a CCD camera (SSC-DC50A, SONY, Tokyo, Japan) was used to take microphotographs for Cam-liposomes. The size distribution for the DPPC-liposomes and Cam-liposomes (liposomes from camel milk phospholipids) before and after extrusion was determined using the Mastersizer by Malvern Instruments Ltd.

2.7. Benzo(a)pyrene- (BAP-) Induced Tumors in a Mouse Model. Female BALB/c mice (6–8 weeks of age) were used to induce tumors in mice. Tumors were induced chemically by injecting benzo(a)pyrene (BAP) dissolved in sesame oil...
at a dose of 250 μg/mouse through subcutaneous route as described earlier [24]. After 90–120 days after BAP injections mice developed palpable tumors.

2.8. Treatment of Tumor-Bearing Mice. Tumor-bearing mice were divided into six different treatment groups and each group was comprised of 10 mice:

1. untreated control,
2. Sham DPPC-liposomes,
3. Sham camel milk liposomes,
4. free etoposide (F-ETP),
5. etoposide-loaded DPPC-liposomes (ETP-DPPC-liposomes),
6. etoposide-loaded camel milk liposomes (ETP-Cam-liposomes).

Tumors were measured regularly using vernier caliper until they reach the volume of 200 mm$^3$. At this point, the treatment of mice was started with drug formulations. Various formulations of etoposide at the dose of 5 mg/kg were administered intraperitoneally to treat tumor-bearing mice once a week for three weeks. The first day of treatment was considered day zero. The size of the tumors was measured regularly according to following formula:

$$V = D \times d^2 \times \frac{\pi}{6},$$

where $V$ = tumor volume, $D$ = biggest dimension, and $d$ = smallest dimension.

The efficacy of the treatment was assessed by analyzing the survival and measuring the change in tumor size of the treated mice.

2.9. Statistics. Survival of the mice was analyzed by log-rank test using Kaplan-Meier curve. The sizes of tumors were compared by one-way ANOVA using Prism software version 6.0 (San Diego, USA).

3. Results and Discussion

3.1. Identification of Major Lipid Components in Camel Milk. The main aim of the present study is not to identify and characterize the phospholipids composition of the camel milk as it has been characterized by many researchers earlier [25, 26]. We characterized the phospholipid composition of camel milk to get the general idea of the presence of the major phospholipids. The TLC plates revealed the presence of PE, PC, LPC, and PI as major phospholipids. Identification of individual phospholipids was achieved by GC-MS and HPLC. It is important to note that interference in the UV/Vis spectrophotometer between etoposide and camel milk phospholipids was observed. This interference necessitated the development of a new and rapid HPLC method not only for phospholipid identification, but also for determination of the encapsulated etoposide into liposomes composed of camel milk phospholipids.

Several mobile phase solvent systems (including isocratic and gradient mobile phase) were, respectively, tested. Their chromatography behavior was simultaneously compared. It was found that gradient mobile phase containing A: acetonitrile/methanol/n-hexane (90:3:7 v/v) with 0.08% triethylamine (TEA) and B: acetonitrile/water/phosphoric acid (75:24:1 v/v) with 0.08% TEA and a flow rate of 1-2 mL/min was successful in separating the four major PLs. These conditions were used to measure the calibration curves of individual phospholipids standards.

Because of the lipophilicity of the phospholipids, we tried to separate them on a Spherisorb C8 column. The investigated phospholipids are varied in their chemical characteristics so we use phosphoric acid to ensure the elution of all the four analytes, to neutralize the charged phosphate group in phospholipids and to reduce secondary interactions between the polar functionality of the phospholipids and any acidic silanols on the stationary phase, which results in strong retention and peak tailing. Under the above-described conditions, the complete separation of the four investigated phospholipids was achieved in less than 12 min. (Figure 1). It shows a typical chromatogram obtained from a standard mixture of PC, PE, PI, and LPC at 210 nm. Peak shapes were improved by both the addition of phosphoric acid and TEA and increasing the temperature. When the temperature of the assay was stable (45°C), the peak appearance and retention times were highly reproducible.

3.2. Validation of the Method

3.2.1. Linearity, Detection, and Quantitative Limits. A linear relationship between the concentrations of PC, PE, PI, and LPC and the UV absorbance at 210 nm was obtained. This linearity was maintained over the concentration ranges of 5–64 μg mL$^{-1}$ for PC, 10–250 μg mL$^{-1}$ for PE, 15–160 μg mL$^{-1}$ for PI, and 50–160 μg mL$^{-1}$ for LPC. The correlation coefficient for each standard curve invariably exceeded 0.997. The values of the detection limit were calculated and were 0.489, 3.05, 4.5, and 9.52 μg mL$^{-1}$ for PC, PE, PI, and LPC, respectively. The results were summarized in Table 1.
assay exhibits the necessary sensitivity and linearity to cover the physiological concentrations of the PLs in milk.

3.3. Precision. Intraday and interday precision were assessed using three concentrations and three replicates of each concentration. The calculated relative standard deviation values were found in Table 2. All the values are acceptable for bioanalytical methods.

3.4. Accuracy. Accuracy was also assessed by the recovery of the added standard; three concentrations each in triplicate to a known concentration of camel milk sample were spiked just before injection. Table 3 shows the results of recoveries. All those recoveries are between 92.41 and 96.74, indicating good accuracy of the recovery of the method.

3.5. Recovery. The recovery of the method was evaluated by comparing the response of extracted camel milk samples spiked before extraction with the response of extracted blank samples spiked just before injection. Table 3 shows the results of recoveries. All those recoveries are between 92.41 and 96.74 and RSDs are less than 2%, indicating good accuracy of the recovery of the method.

The scope of the protocol was to choose a mobile phase that provides a good selectivity with no too large cutoff of absorbance at a wavelength below 210 nm. These conditions were met by using a mixture of A: acetonitrile/methanol/n-hexane (90: 3: 7 v/v) with 0.08% triethylamine (TEA) and B: acetonitrile/water/phosphoric acid (75: 25: 1 v/v) with 0.08% TEA and a flow rate of 1-2 mL/min; column temperature, 45°C; and UV at 210 nm.

3.6. Gas Chromatography-Mass Spectrometry (GC/MS). The phospholipid fractions were subjected to capillary gas chromatography-mass spectrometry for profiling the phospholipid content in a total run of 45 minutes and full mass spectrum between 100 and 1000 was obtained. The main phospholipid constituents based on their characteristic mass fragments were PE, PC, PI, and LPC.

Lyso phosphatidylcholine (LPC) showed the quasimolecular ion peak at m/z 522 [M + H]+ assigned to the protonated molecule and base peak at m/z 183 corresponding to phospholipid [PO4(CH2)2N(CH3)3 + H]+ moiety. The ion peak at m/z 282 [FA + H]+ revealed octadecenoic fatty acid residue (18:1). Accordingly, the phospholipid species were assigned octadecenoic 18:1 LPC (Figure 2(a)).

Phosphatidylethanolamine (PE) provided an ion peak at m/z 181 characterizing the loss of phosphoethanolamine moiety. The quasimolecular ion peak at m/z 761 [M + H]+, the characteristic phospholipid base peak at m/z 183 [PO4(CH2)2N(CH3)3 + H]+, and low abundance peaks at m/z 580 assigned to [M--phospholipid]+. The ion peaks at m/z 494, 268, and m/z 506, 256 were assigned to the loss of octadecanoic 18:0 and hexadecanoic 16:0 fatty acid moieties, respectively, which identify this species as 18:0/16:0 diacyl PC (Figure 2(b)).

Phosphatidylcholine (PC) was recognized from quasimolecular ion peak at m/z 761 [M + H]+, the characteristic phospholipid base peak at m/z 183 [PO4(CH2)2N(CH3)3 + H]+, and low abundance peaks at m/z 580 assigned to [M--phospholipid]+. The ion peaks at m/z 494, 268, and m/z 506, 256 were assigned to the loss of octadecanoic 18:0 and hexadecanoic 16:0 fatty acid moieties, respectively, which identify this phospholipid species as 20:0/18:1 diacyl PE (Figure 2(c)).

Phosphatidyl ethanolamine (PE), the negative mode ionization spectrum, showed an ion peak at m/z 864 [M + H]+ and an ion peak at m/z 180 characterizing the loss of a phosphatidylethanolamine moiety. The quasimolecular ion peak at m/z 789 [M + H]+, the ion peaks at m/z 461, 312 and at m/z 491, 282 were assigned to eicosanoic 20:0 and octadecanoic 18:1 acids, respectively, which identified this phospholipid species as 20:0/18:1 diacyl PE (Figure 2(d)).

3.7. Liposome Preparation and Drug Encapsulation. Microphotographs obtained from the optical microscopy show that MLVs liposomes were successfully prepared from a mixture of phospholipid isolated from camel milk by using the thin film hydration method (Figure 3). The vesicle size distributions for DPPC-liposomes and Cam-liposomes before and after the extrusion through 200 nm followed by 100 nm polycarbonate membrane (10 times for each) were determined using a Malvern Mastersizer. Figures 4 and 5 show that the repetitive extrusion of MLVs through the stacked polycarbonate membrane with 200 nm followed by 100 nm pore size after 10 freeze-thaw cycles resulted in small unilamellar vesicles (SUVs) exhibiting a relatively homogeneous size distribution. The size distribution for DPPC-liposomes before extrusion was 2312 nm for the first peak with 80.65% intensity and 5557 nm for the second peak with 19.4% intensity (Figure 4(a)). The size distribution after 10-time extrusions through 200 nm polycarbonate
Table 2: Intraday and interday precision of the proposed method.

| Parameter | PC 10 µg mL\(^{-1}\) | PC 30 µg mL\(^{-1}\) | PE 50 µg mL\(^{-1}\) | PE 20 µg mL\(^{-1}\) | PE 80 µg mL\(^{-1}\) | PE 120 µg mL\(^{-1}\) | PI 20 µg mL\(^{-1}\) | PI 50 µg mL\(^{-1}\) | PI 100 µg mL\(^{-1}\) | PI 60 µg mL\(^{-1}\) | LPC 90 µg mL\(^{-1}\) | LPC 120 µg mL\(^{-1}\) |
|-----------|------------------------|-----------------------|----------------------|----------------------|----------------------|----------------------|---------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Intraday  |                        |                       |                      |                      |                      |                      |                     |                      |                      |                      |                     |                     |
| 1         | 101.07                 | 101.74                | 100.89               | 98.25                | 97.7                 | 103.91               | 97.12               | 96.37                | 96.61                | 90.00                | 87.50                | 96.51                |
| 2         | 101.80                 | 102.65                | 101.08               | 99.01                | 101.54               | 101.1                | 99.51               | 100.24               | 94.43                | 91.25                | 89.50                | 99.63                |
| 3         | 93.98                  | 104.94                | 102.99               | 99.25                | 99.44                | 96.91                | 99.11               | 97.42                | 91.50                | 86.25                | 98.1                 |                     |
| Mean      | 100.61                 | 103.11                | 101.65               | 99.79                | 99.49                | 101.48               | 97.84               | 98.57                | 96.15                | 90.91                | 87.75                | 98.08                |
| S.D       | 1.46                   | 1.64                  | 1.16                 | 2.05                 | 1.93                 | 2.25                 | 1.44                | 1.99                 | 1.54                 | 0.80                 | 1.63                 | 1.56                 |
| R.S.D     | 1.45                   | 1.59                  | 1.14                 | 2.05                 | 1.93                 | 2.21                 | 1.47                | 2.01                 | 1.59                 | 0.87                 | 1.85                 | 1.59                 |
| Interday  |                        |                       |                      |                      |                      |                      |                     |                      |                      |                      |                     |                     |
| 1         | 99.63                  | 101.03                | 102.65               | 100.56               | 99.33                | 101.19               | 95.37               | 96.61                | 99.11                | 98.85                | 98.9                 | 96.98                |
| 2         | 99.83                  | 101.27                | 99.82                | 98.86                | 100.17               | 99.22                | 100.80              | 98.94                | 101.5                | 99.25                | 98.99                |                     |
| 3         | 101.4                  | 96.39                 | 103.88               | 98.33                | 95.63                | 103.22               | 98.18               | 99.88                | 99.75                | 97.76                | 101.00               | 97.56                |
| Mean      | 100.28                 | 99.56                 | 102.11               | 99.57                | 97.94                | 101.52               | 97.59               | 99.09                | 99.37                | 99.71                | 97.84                |                     |
| S.D       | 0.969                  | 2.75                  | 2.08                 | 1.13                 | 2.01                 | 1.55                 | 1.99                | 2.20                 | 0.42                 | 1.92                 | 1.12                 | 1.03                 |
| R.S.D     | 0.966                  | 2.76                  | 2.05                 | 1.13                 | 2.05                 | 1.52                 | 2.03                | 2.22                 | 0.43                 | 1.93                 | 1.12                 | 1.05                 |
| Sample number | Taken (μg mL\(^{-1}\)) | Found (μg mL\(^{-1}\)) | % of recovery | Taken (μg mL\(^{-1}\)) | Found (μg mL\(^{-1}\)) | % of recovery | Taken (μg mL\(^{-1}\)) | Found (μg mL\(^{-1}\)) | % of recovery | Taken (μg mL\(^{-1}\)) | Found (μg mL\(^{-1}\)) | % of recovery |
|---------------|--------------------------|--------------------------|---------------|--------------------------|--------------------------|---------------|--------------------------|--------------------------|---------------|--------------------------|--------------------------|---------------|
| 1             | 10                       | 9.55                     | 95.53         | 20                       | 19.34                    | 96.74         | 20                       | 18.62                    | 93.14         | 60                       | 57.00                    | 95.01         |
| 2             | 30                       | 28.39                    | 94.64         | 80                       | 74.43                    | 93.04         | 50                       | 46.87                    | 93.75         | 90                       | 84.05                    | 93.39         |
| 3             | 50                       | 46.20                    | 92.41         | 120                      | 114.6                    | 95.5          | 120                      | 114.98                   | 95.82         | 120                      | 115.27                   | 96.06         |
| Mean          |                          |                          | 94.19         |                          |                          | 95.09         |                          |                          | 94.23         |                          |                          | 94.82         |
| S.D.          |                          |                          | 1.60          |                          |                          | 1.88          |                          |                          | 1.40          |                          |                          | 1.34          |
| R.S.D.        |                          |                          | 1.69          |                          |                          | 1.97          |                          |                          | 1.48          |                          |                          | 1.41          |
Figure 2: MS spectrograms of (a) LPC, (b) PC, (c) PE, and (d) PL.

Figure 3: Microphotographs for liposomes prepared from camel milk phospholipids.
Figure 4: Size distribution for liposomes prepared from DPPC. (a) MLVs liposomes before extrusion, (b) liposomes after extrusion 10 times through 200 nm polycarbonate membrane, and (c) SUVs liposomes after extrusion 10 times through 100 nm polycarbonate membrane.

Figure 5: Size distribution for liposomes prepared from camel milk phospholipids. (a) MLVs liposomes before extrusion, (b) liposomes after extrusion 10 times through 200 nm polycarbonate membrane, and (c) SUVs liposomes after extrusion 10 times through 100 nm polycarbonate membrane.

The size of Cam-liposomes after hydration (before extrusion) was smaller than DPPC-liposomes with only one size distribution peak at 1242 nm with 100% intensity (Figure 5(a)). Also Cam-liposomes were smaller after 10-time extrusions through 200 nm polycarbonate membrane with size distribution at 95.2 nm for the first peak and
532.1 nm for the second peak (Figure 5(b)). After 10-time extrusions of Cam-liposomes through 100 nm polycarbonate membrane, the size distribution was 75.75 nm with 100% intensity (Figure 5(c)). It is important to note that the size distribution of Cam-liposomes indicates that Cam-liposomes were smaller than that for DPPC-liposomes before and after extrusion.

Etoposide was encapsulated into DPPC-liposomes with the trapping efficiency of not more than 18%, while the percent of etoposide encapsulation was increased in Cam-liposomes to 22%. The increase in the % trapping efficiency of etoposide into Cam-liposomes may be due to their phospholipid composition.

3.8. In Vivo Activity of Various Etoposide Formulations against Experimental Fibrosarcoma. The in vivo activity of various etoposide formulations against experimental fibrosarcoma was assessed in a murine model. Chemotherapy was started when tumors attained the size in the range of 150–200 mm³. Fibrosarcoma-bearing mice were treated with a single weekly dose of 5 mg/kg of free ETP or ETP-DPPC-liposomes or ETP-Cam-liposomes through intraperitoneal route for three weeks. During and after the chemotherapy the size of the tumors was regularly measured using digital vernier calipers. Among the all treatment groups, the tumors showed the least progression or delayed growth in mice treated with ETP-Cam-liposomes, whereas the tumors in mice treated with free ETP showed more growth compared to those treated with ETP-DPPC-liposomes or ETP-Cam-liposomes (Figure 6). However, it is important to note that once the chemotherapy was stopped, tumor size started to increase very fast. Most of the mice in group treated with ETP-Cam-liposomes died in between 40 and 60 days after treatment (Figure 7).

Besides assessing the effect of chemotherapy on the size of tumors, the effect of various formulations of etoposide on the survival of tumor-bearing mice was also observed. Consistent with its effect in restricting tumor size, chemotherapy with ETP-Cam-liposomes also imparted greater survival to fibrosarcoma-bearing mice. Tumor-bearing mice treated with ETP-Cam-liposomes died within 120 days, whereas mice in the groups treated with free ETP or ETP-DPPC-liposomes died within 70 days and 90 days, respectively (Figure 7).

There have been many beneficial effects associated with the use of camel milk in human beings [27–29]. Camel milk has been shown to possess therapeutic value in the treatment of cancer [30–32]. Most of the beneficial effects are associated with the protein components present in camel milk. But the role of phospholipid components of camel milk has not been explored. In the present study, we exploited the camel milk phospholipids for the preparation of liposomes and used them as drug delivery systems for anticancer drug etoposide against fibrosarcoma in a murine model. The characterization of the phospholipids isolated from camel milk predominantly showed the presence of PE, PC, PI, and LPC. Camel milk contains interesting lipid composition as characterized by the different methods used in the present study. The presence of phosphatidylethanolamine (PE) in camel milk phospholipid liposomes may play important role...
in increasing the anticancer efficacy of etoposide. Earlier studies have shown the increased efficacy of anticancer drug cisplatin entrapped in PE-containing liposomes [33]. This is also confirmed by the results of the present study that showed greater efficacy of ETP-Cam-liposomes compared to the ETP-DPPC-liposomes or free ETP. Commonly used cationic liposomes also show greater toxicity against normal cells, whereas the presence of PE imparts a negative charge to the liposomes and reduces their toxicity to normal cells.

4. Conclusions

This study tests a chromatographic protocol for the separation and qualitative/quantitative determination of four PLs in camel milk by HPLC with a UV detector. The procedure was applied for the determination of the PE, PC, PI, and LPC in camel milk. This is the first study in which camel milk phospholipids were used to prepare liposomes to deliver anticancer drugs. The results of the present study showed that etoposide and camell milk phospholipid liposomes show greater anticancer activity against fibrosarcoma in a murine model compared to free etoposide or etoposide entrapped in DPPC-liposomes. This suggests that camel milk phospholipids may prove to be better and more effective delivery systems for anticancer drugs in human beings.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This work is a part of a project supported by grants from the National Plan for Science, Technology and Innovation (10-NAN-1226-09), Qassim University.

References

[1] J. Jia, F. Zhu, X. Ma, Z. W. Cao, Y. X. Li, and Y. Z. Chen, “Mechanisms of drug combinations: Interaction and network perspectives,” Nature Reviews Drug Discovery, vol. 8, no. 2, pp. 111–128, 2009.

[2] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004.

[3] J. L. Nitiss, “Targeting DNA topoisomerase II in cancer chemotherapy,” Nature Reviews Cancer, vol. 9, no. 5, pp. 338–350, 2009.

[4] D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 307–320, 2005.

[5] L. Kelland, “The resurgence of platinum-based cancer chemotherapy,” Nature Reviews Cancer, vol. 7, no. 8, pp. 573–584, 2007.

[6] A. Martoni, A. Bellucco, N. Canova, and F. Pannuti, “Four-year analysis of platinum and anthracycline combination for ovarian cancer,” Oncology, vol. 46, no. 2, pp. 109–116, 1989.

[7] O. S. Nielsen, P. Dombernowsky, H. Mouridsen et al., “Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group,” Sarcoma, vol. 4, no. 1-2, pp. 31–35, 2000.

[8] J. Tate Thigpen, M. F. Brady, H. D. Homesley et al., “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 22, no. 19, pp. 3902–3908, 2004.

[9] M. Bigioni, A. Benzo, C. Irrissuto et al., “Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 4, pp. 621–629, 2008.

[10] L. Zhao, M. G. Wientjes, and J. L. Au, “Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses,” Clinical Cancer Research, vol. 10, no. 23, pp. 7994–8004, 2004.

[11] Y. Pommier, E. Leo, H. Zhang, and C. Marchand, “DNA topoisomerases and their poisoning by anticancer and antibacterial drugs,” Chemistry and Biology, vol. 17, no. 5, pp. 421–433, 2010.

[12] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007.

[13] M. E. Davis, Z. Chen, and D. M. Shin, “Nanoparticle therapeutics: an emerging treatment modality for cancer,” Nature Reviews Drug Discovery, vol. 7, no. 9, pp. 771–782, 2008.

[14] J. L. Markman, A. Rekechenetskiy, E. Holler, and J. Y. Ljubimova, “Nanomedicine therapeutic approaches to overcome cancer drug resistance,” Advanced Drug Delivery Reviews, vol. 65, no. 13–14, pp. 1866–1879, 2013.

[15] A. Candoni, A. Michelutti, E. Simeone, D. Damiani, M. Baccarani, and R. Fanin, “Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins,” European Journal of Haematology, vol. 77, no. 4, pp. 293–299, 2006.

[16] T. M. Allen, G. A. Austin, A. Chonn, L. Lin, and K. C. Lee, “Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1061, no. 1, pp. 56–64, 1991.

[17] U. Schroeder, “Nanoparticle technology for delivery of drugs across the blood–brain barrier,” Journal of Pharmaceutical Sciences, vol. 87, no. 11, pp. 1305–1307, 1998.

[18] G. Konuspaveva, B. Faye, and G. Loiseau, “The composition of camel milk: a meta-analysis of the literature data,” Journal of Food Composition and Analysis, vol. 22, no. 2, pp. 95–101, 2009.

[19] J. M. Evers, R. G. Haverkamp, S. E. Holroyd, G. B. Jameson, D. S. Mackenzie, and O. J. McCarthy, “Heterogeneity of milk fat globule membrane structure and composition as observed using fluorescence microscopy techniques,” International Dairy Journal, vol. 18, no. 12, pp. 1081–1089, 2008.

[20] S. Gallier, D. Gragson, R. Jiménez-Flores, and D. Everett, “Using confocal laser scanning microscopy to probe the milk fat globule membrane and associated proteins,” Journal of Agricultural and Food Chemistry, vol. 58, no. 7, pp. 4250–4257, 2010.

[21] C. Lopez, M.-N. Madec, and R. Jimenez-Flores, “Lipid rafts in the bovine milk fat globule membrane revealed by the lateral segregation of phospholipids and heterogeneous distribution of glycoproteins,” Food Chemistry, vol. 120, no. 1, pp. 22–33, 2010.
[22] G. Contarini and M. Povolo, “Phospholipids in milk fat: composition, biological and technological significance, and analytical strategies,” *International Journal of Molecular Sciences*, vol. 14, no. 2, pp. 2808–2831, 2013.

[23] H. Maswadeh, S. Hatziantoniou, C. Demetzos, K. Dimas, A. Georgopoulos, and M. Rallis, “Encapsulation of Vinblastine into new liposome formulations prepared from triticum (wheat germ) lipids and its activity against human leukemic cell lines,” *Anticancer Research*, vol. 20, no. 6, pp. 4385–4390, 2000.

[24] A. Khan, A. A. Khan, V. Dwivedi, M. G. Ahmad, S. Hakeem, and M. Owais, “Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice,” *Molecular Medicine*, vol. 13, no. 5-6, pp. 266–276, 2007.

[25] Z. Farah, “Composition and characteristics of camel milk,” *Journal of Dairy Research*, vol. 60, no. 4, pp. 603–626, 1993.

[26] A. M. S. Gorban and O. M. Izzeldin, “Fatty acids and lipids of camel milk and colostrum,” *International Journal of Food Sciences and Nutrition*, vol. 52, no. 3, pp. 283–287, 2001.

[27] A. A. Korish, “The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines,” *Hormone and Metabolic Research*, vol. 46, no. 6, pp. 404–411, 2014.

[28] R. P. Agrawal, P. Tantia, S. Jain, R. Agrawal, and V. Agrawal, “Camel milk: a possible boon for type 1 diabetic patients,” *Cellular and Molecular Biology*, vol. 59, no. 1, pp. 99–107, 2013.

[29] A. A. Korish and M. M. Arafah, “Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease,” *BMC Complementary and Alternative Medicine*, vol. 13, article 264, 2013.

[30] A. A. Alhaider, A. G. M. Abdel Gader, N. Almeshaal, and S. Saraswati, “Camel milk inhibits inflammatory angiogenesis via downregulation of proangiogenic and proinflammatory cytokines in mice,” *APMIS*, vol. 122, no. 7, pp. 599–607, 2014.

[31] H. M. Habib, W. H. Ibrahim, R. Schneider-Stock, and H. M. Hassan, “Camel milk lactoferrin reduces the proliferation of colorectal cancer cells and exerts antioxidant and DNA damage inhibitory activities,” *Food Chemistry*, vol. 141, no. 1, pp. 148–152, 2013.

[32] H. M. Korashy, Z. H. Maayah, A. R. Abd-Allah, A. O. S. El-Kadi, and A. A. Alhaider, “Camel milk triggers apoptotic signaling pathways in human hepatoma HepG2 and breast cancer MCF7 cell lines through transcriptional mechanism,” *Journal of Biomedicine and Biotechnology*, vol. 2012, Article ID 593195, 9 pages, 2012.

[33] T.-L. Hwang, W.-R. Lee, S.-C. Hua, and J.-Y. Fang, “Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas,” *Journal of Dermatological Science*, vol. 46, no. 1, pp. II–20, 2007.